GLP-1, Honestly

Ninety-one days. The scale says 208 — twenty-two pounds just gone, the twenty-two that used to sit on the table with his belt undone after dinner. He should feel like a winner, and in the mirror at 6am, under the bathroom light he's always hated, he almost does. Then he leans in. His face has thinned in a way faces don't at forty-four — the cheeks dropped, a hollowness under the eyes, a slackness along the jaw. He lifts an arm and flexes the way men do when no one's watching, and the muscle that answers is smaller, softer, quieter than it was in March. Less arm. Less him. The scale is winning. Something else is losing. And nobody at the clinic said a word about the second part.

Here's the honest starting point, the one balance-for-its-own-sake writers won't give you: it works. Spectacularly. GLP-1 is the most effective fat-loss tool ever put in a syringe, and pretending otherwise to sound measured is its own kind of lie. But it works and you did it right are two different sentences. The first is about the scale. The second is about what you actually lost to move it, and what happens the day you stop. Two men drop the same twenty-two pounds — one keeps his muscle and walks away lean, the other burns through muscle and rebounds a year later heavier than he started. Same number. Opposite outcome. The clinic sold you the number. This is the game underneath it.

The drug doesn't melt anything. GLP-1 is a gut hormone you release after eating; these are long-acting versions of it. They work by turning the volume down on hunger — acting on the appetite centres of the brain to kill the “food noise,” and slowing how fast your stomach empties so you feel full on less. You simply want less food, powerfully, and a calorie deficit follows. Tirzepatide adds a second hormone (GIP); retatrutide adds a third (glucagon) that nudges energy expenditure up a little. But make no mistake — across all three, the engine is eat less, not burn more. That answers the question everyone Googles: it suppresses appetite. The weight you lose is the weight of a sustained deficit — and some of that, left unmanaged, is muscle.

How Do Ozempic, Mounjaro & Other GLP-1 Agonists Work?Zachary Knight & Andrew Huberman · Huberman Lab

No willpower hack in history comes close. In the landmark trials, all with lifestyle support: semaglutide (STEP 1) averaged ~15% of body weight at 68 weeks. ¹ Tirzepatide (SURMOUNT-1) hit ~21% at the top dose — and in the first head-to-head, SURMOUNT-5, it beat semaglutide outright (~20% vs ~14%). ²³ Retatrutide, the triple agonist still in trials, reached ~24% at 48 weeks with the curve still falling. ⁴ For a 200lb man that's 30–48 pounds. These are real, and they're why the drugs broke the internet. Set your own numbers — and watch the part the ads leave out:

Here's what the projector just showed you, and what the clinic didn't. When you lose weight this fast, a real chunk of it isn't fat — it's lean mass. Across GLP-1 trials with body-composition scans, muscle and other fat-free mass has typically made up a quarter to nearly 40% of the total lost. Muscle is your metabolic engine, your strength, and the very thing that keeps the weight off later — and it's the first thing the process takes if you let it. As for “ozempic face”: it isn't a mysterious drug effect. Your face is made of the fat you're stripping, and losing it fast — with no muscle tone underneath to hold the frame — is what leaves it gaunt. Slow the loss, keep the muscle, and the face mostly takes care of itself.

Cause for caution with weight loss drugs like OzempicPeter Attia MD

This is the section that decides everything, and it's shockingly simple. Two levers defend your muscle while the fat comes off. Protein: aim for 1.6–2.2g per kg of bodyweight a day. The trap is that the drug craters your appetite, so protein has to become a bigger slice of a much smaller pie — most men accidentally under-eat it badly because they're just not hungry. Protein first, every meal; a daily shake when food feels like a chore. Resistance training: 2–4 sessions a week, progressive. Protein is the raw material; lifting is the instruction that tells your body to keep the muscle instead of burning it. Cardio is great for your heart and does nothing to save your arms. And go slower — roughly 0.5–1% of bodyweight a week; faster, and more of what leaves is muscle. Here's your number:

Be blunt with yourself now: this is a maintenance drug, not a cure. The withdrawal trials are unambiguous. In STEP 4, people who stopped semaglutide and switched to placebo started regaining immediately, while those who stayed on kept losing — clean causal proof the drug is doing work your habits aren't. ⁵ And in the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping. ⁶ This isn't a willpower failure; it's pharmacology — the appetite biology comes back. So the whole game is to use the months on the drug to build the thing you'll stand on after it: the muscle, the training habit, the protein-first pattern. Some people stay on a low maintenance dose long-term, and there's no shame in it — obesity is chronic. What fails is treating the shot as a sprint.

New insights on GLP-1 agonists — Ozempic, Wegovy, Mounjaro & morePeter Attia MD

These are real medicines with a real side-effect profile — which is exactly why they belong under a licensed clinician, not a group chat. The dominant reality is GI: nausea, constipation, sometimes vomiting, worst early and largely tamed by titrating the dose up slowly (there's no prize for reaching a high dose fast). Rapid weight loss raises the risk of gallstones. Pancreatitis is rare but real — severe, persistent abdominal pain radiating to the back is a stop-and-call-your-doctor sign. There's a boxed warning for thyroid C-cell tumours (seen in rodents; human relevance unproven) that makes these a hard no if you have a personal or family history of medullary thyroid cancer or MEN2. Manage hydration and electrolytes; the fatigue people blame on “ozempic” is often just under-eating and under-drinking. None of this is a reason to avoid the drug. It's the reason to run it properly, with monitoring.

The molecule in the compounded vial and the branded pen is, in principle, the same. The supply chain is not — and that's the part that can hurt you. Brand products — Wegovy and Zepbound for weight loss, Ozempic and Mounjaro for diabetes — are FDA-approved, standardized dose per pen, quality-controlled, and expensive. Compounded semaglutide and tirzepatide are mixed by licensed pharmacies and are not FDA-approved; they exploded during the official shortages, and as those shortages resolved the legal basis for mass-compounding narrowed. Consistency and potency can vary, which is precisely why who prescribes and fills it matters more than the price. The one non-negotiable line: if you're going to do this, do it through a licensed prescriber who examines you, doses you, and follows up — never a grey-market “research” vial off the internet. Same molecule, completely different risk. Our compound pages point only to licensed telehealth routes.

The GLP-1 compounds — always clinician-managed, never grey-market injectables:

Tirzepatide

2.5–15 mg · Weekly

Get prescribed →

Retatrutide

1–12 mg · Weekly

So here's the honest verdict the ad and the influencer left out. GLP-1 is not a shortcut — it's a tool, a genuinely great one, maybe the best we've ever had for this, and like any great tool it does exactly what the hands holding it decide. In the hands of the man who respects it, it's extraordinary: he eats his protein like it's a job, he lifts to keep what he walked in with, he watches the mirror and not just the scale, and he knows the shot was never the plan — it was the thing that made the plan possible. He comes out lean, strong, and off the drug on his own terms. In the hands of the man who thinks the shot is the plan, it's a trap with a great first act: the weight falls off, the muscle and the face go with it, and when he stops — everyone stops — it all comes home and finds him weaker than it left him. Same drug. Same dose. Opposite lives. The medicine will do its part. The only question is whether you'll do yours.